Neuromodulation Addiction Treatments Move Home |
Take our Addiction Test
Find a therapist to overcome addiction
TMS and other neuromodulation successes have shown the future of circuit-based addiction treatment.
In the future, drug craving and relapse could be anticipated and blocked with neuromodulation.
Wearable devices have and can be developed to provides safe and effective at-home treatment
For much of modern psychiatry, the brain has been treated indirectly with medications altering neurotransmitters—serotonin, dopamine, norepinephrine—under the assumption that downstream effects will rebalance mood or drug cravings. Operating apart from dysfunction in the brain’s circuits, this approach has produced meaningful advances.
In contrast, neuromodulation directly targets the electrical activity of brain networks. And what began as a laboratory curiosity has evolved into a clinical treatment tool, moving from hospitals to offices and, now, to patient homes.
Modern noninvasive neuromodulation began in the 1980s with transcranial magnetic stimulation (TMS). The first device was developed in the early 1980s and sold as the Magstim Model 200. It was a revolutionary, noninvasive method for stimulating the brain and treating depression.
The key conceptual leap occurred in the 1990s through the work of neurologist and psychiatrist Mark George of the Medical University of South Carolina. Back then, neuroimaging studies revealed that brain patterns in depression: reduced activity in the left dorsolateral prefrontal cortex (DLPFC) and disrupted communication between the prefrontal and limbic regions. George wondered whether psychiatric disorders reflected dysfunctional activity in specific circuits and whether targeted stimulation could restore circuits to health.
Using repetitive TMS (rTMS), George’s group applied high-frequency stimulation to the left DLPFC, demonstrating antidepressant effects. The result reframed TMS from a diagnostic probe into a therapeutic intervention. It also helped establish “circuit psychiatry”—the idea that mental disorders are also disorders of network dynamics.
Neuromodulation in Addiction Medicine
In 2014, the U.S. Food and Drug Administration cleared the electroauricular device (EAD) the NSS-2 Bridge Neurostimulation System, an early translation of the concept, for use in acupuncture. Authorization expanded in 2017 to support reducing opioid withdrawal symptoms. The Bridge is a small, disposable, battery-powered device worn behind the ear for five days during acute withdrawal. It delivers continuous electrical stimulation to auricular branches of cranial nerves. The Bridge provides continuous, automated stimulation in an ambulatory setting, enabling a drug-free, home-based intervention during early opioid withdrawal, when relapse risk is highest.
Another device, the Sparrow Therapy System, cleared by the FDA in 2021, delivers transcutaneous auricular neurostimulation (tAN) without percutaneous electrodes. This device is useful in facilitating transition to medications for opioid use........